"I absolutely hate unblinding Phase III studies, but in this case I'm quite happy with the results."
– Tim Ruane, CEO of InSite Vision Inc., discussing positive findings from the first Phase III trial of BromSite
"It's a completely open door now, in mRNA technology. The speed, efficiency and lower cost of mRNA likely will now come to the attention of other pharma firms."
– Ingmar Hoerr, CEO, CureVac GmbH, commenting on the AstraZeneca deal with Moderna
"Where we landed I believe is a very good deal for both companies. We have a deal with very attractive financial terms and the opportunity to become a global orphan company overnight."
– Francois Nader, CEO, NPS Pharmaceuticals Inc., whose company regained full worldwide rights to teduglutide (Gattex) and recombinant human parathyroid hormone 1-84 (PTH 1-84/Preotact) from Takeda Pharmaceutical Co. Ltd.